Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Clinical trial NCT05859776 · UNKNOWN
Trial details
- NCT number
- NCT05859776
- Sponsor
- AsclepiX Therapeutics, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-19
- Primary completion
- 2025-03-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.